Onset: No acute pharmacological effect noticeable for typical use. Effects are cumulative over 4-12 weeks at 3-6 g/day.

First-time impressions:

• Strong "ocean" / "pond" / "fishy seaweed" smell and taste when in powder form. Capsules and tablets bypass this.
• Greenish-to-blackish stool within 1-2 days of starting at 3+ g/day. Normal, harmless — the chlorophyll and phycocyanin pigments transit largely undigested through the colon. Often mistaken for melena (GI bleeding) by first-time users.
• Mild GI upset in 5-15% of users in the first week: bloating, gas, soft stool. Usually resolves with continued use or with starting at 1 g/day and titrating up.
• Some users report a mild "energy" or "alertness" feeling — likely from a mix of iron, B-vitamins, and general nutritional fortification rather than direct stimulation.

4-12 week effects (if real for the user):

• Improvements in subjective allergic-rhinitis symptoms in seasonal sufferers (most consistent subjective signal).
• Modest BP reduction noticeable on home cuff in hypertensives.
• Subjective recovery improvement in athletes — less DOMS, faster between-session recovery. Plausibly the antioxidant + GLA effect.
• No appreciable subjective effect in most healthy young adults already eating well.

Honest variability: Effect size is modest enough that placebo + general dietary improvement (people who add spirulina often also clean up their diet) explains a substantial portion of subjective benefit. The cleanest signals are objective (BP, lipid panel, ferritin in deficient populations) rather than subjective.

• Pharmacological tolerance: Not documented. Effects on BP, lipids, immune markers are dose-and-duration-dependent, not subject to receptor downregulation.
• GI tolerance: Builds within 1-2 weeks; initial bloating and gas resolve.
• Cycling not necessary for the BP/lipid/general-health indication.
• Optional rotation: Some practitioners rotate spirulina/chlorella/moringa quarterly to vary micronutrient profile and reduce single-source heavy-metal exposure risk. Reasonable hedge but no evidence advantage.
• Off-period considerations: Effects on lipids and BP fade over 4-8 weeks of discontinuation. Need to maintain for sustained benefit.

Synergistic with

• Vitamin C — enhances iron absorption from spirulina; recommended co-administration if using for iron support.
• Omega-3 (EPA/DHA) — complements spirulina's GLA + ALA fatty-acid profile; combined anti-inflammatory effect.
• Vitamin D3 + K2 — common stacker among community users (dopamine.club: 81 co-mentions with D3). No pharmacokinetic interaction; both general-health basal supplements.
• Curcumin — additive antioxidant + anti-inflammatory mechanisms (Nrf2 pathway, COX-2 inhibition).
• Resistance/endurance training — 2025 cardiometabolic meta found spirulina + exercise outperformed spirulina alone for HDL-C, LDL-C, and body composition.
• Hawaiian Pacifica specifically + diet rich in citrus / pepper — pepper's piperine may modestly enhance phycocyanin bioavailability (mechanism: CYP inhibition + intestinal absorption modulation); evidence weak but plausible.

Avoid stacking with

• High-dose iron supplements (>30 mg elemental) — risk of cumulative iron overload over months at 5 g spirulina/day. Get ferritin + transferrin sat checked before stacking.
• Immunosuppressants (cyclosporine, tacrolimus, methotrexate, biologics) — spirulina's immune-stimulating profile theoretically counteracts; clinical relevance unclear, but caution advised.
• Warfarin / anticoagulants — variable vitamin K content can affect INR. Maintain consistent dose if combined; INR monitoring.
• Active autoimmune flares — pause spirulina during flares pending rheumatology guidance.

Neutral / safe co-administration

• Most multivitamins, magnesium, zinc, creatine, beta-alanine, ashwagandha, rhodiola, theanine, glycine, taurine — no known interactions.
• Coffee/caffeine — fine; just avoid taking spirulina simultaneously with coffee if using for iron support (tannins reduce iron absorption).
• Statins — no relevant interaction; mechanism does not overlap.
• SSRIs/SNRIs — no known interaction. The "serotonin syndrome" community flag on dopamine.club (5 mentions) appears speculative; no published case reports.

Spirulina's interaction profile is low-risk — it's a whole-food, not a high-affinity ligand. Main concerns are nutrient-overload and immune-modulation pharmacodynamic effects rather than CYP-mediated PK interactions.

1. Anticoagulants (warfarin) — monitor INR

• Variable vitamin K content across batches can subtly affect anticoagulation. Significance is modest at typical doses but real. Maintain consistent dose and brand; alert prescriber of any change.

2. Immunosuppressants — pharmacodynamic antagonism

• Cyclosporine, tacrolimus, methotrexate, biologics (TNF-α inhibitors, IL-17 blockers, etc.). Spirulina upregulates NK-cell activity and IL-2 production in preclinical models — theoretically counteracting immune suppression. Clinical case reports of organ-transplant rejection on spirulina are absent but caution is justified. Avoid in transplant patients without specific physician approval.

3. Iron supplements / multivitamins with iron — cumulative iron loading

• 5 g spirulina = ~1.5 mg iron. A daily multivitamin (8-18 mg) plus iron-fortified cereal plus red meat plus spirulina can push total iron above safe upper limits in hemochromatosis (HFE carriers, ~10% Caucasian population for any C282Y or H63D allele). Get ferritin + transferrin sat before chronic high-dose use.

4. Levothyroxine — possible absorption interference

• Theoretical: any high-mineral supplement (iron, calcium) can chelate levothyroxine and reduce its absorption if taken simultaneously. Separate by ≥4 hours.

5. ACE inhibitors / ARBs — additive BP-lowering

• Spirulina has its own modest ACE-inhibitor activity via phycocyanin peptides. Combined with prescription ACE-I or ARB, modest additive BP drop possible. Monitor BP especially during initiation. Not dangerous but worth knowing.

6. NSAIDs / aspirin — possible COX-2 additive effect

• Phycocyanin is a selective COX-2 inhibitor. Combined with NSAIDs, additive GI-protective effect is possible (or, conversely, COX-2-selective NSAID + spirulina may have minor cardiovascular implication theoretically — no clinical evidence).

7. Diabetes medications (metformin, sulfonylureas, insulin) — additive glucose lowering

• Spirulina modestly improves glucose homeostasis per 2025 meta. If diabetic and on hypoglycemics, monitor for hypoglycemia symptoms when starting.

8. Chemotherapy — uncertain

• Spirulina has antioxidant effects that might protect normal tissues but could also theoretically blunt oxidative-stress-dependent chemotherapy (e.g., doxorubicin). Avoid during active chemotherapy unless approved by oncology.

9. CYP enzymes — minimal interaction. Spirulina does not have meaningful CYP inhibitor/inducer activity at dietary doses. PK-interaction risk is very low compared to phytochemicals like St. John's Wort, grapefruit, or curcumin.

10. Levodopa / Parkinson's drugs — no known interaction (the amino acid content is low enough that the phenylalanine/tyrosine content shouldn't compete meaningfully).

Pharmacogenomic considerations for spirulina are minimal because it acts as a nutritional whole-food rather than a metabolized drug. Three indirect angles matter:

HFE polymorphism (hemochromatosis-related): ~10% of Caucasians carry at least one HFE C282Y or H63D allele; ~0.3-0.5% are homozygous C282Y (clinical hemochromatosis risk). For carriers, spirulina's heme-analog iron stacked with other dietary iron may accelerate iron loading over years. Practical: get ferritin + transferrin sat baseline before high-dose chronic use; if C282Y homozygous, avoid daily spirulina at >3 g/day.

PKU (PAH gene mutations): Phenylketonuria patients (1 in 10-25k Caucasians) cannot metabolize phenylalanine. Spirulina's ~5% phenylalanine content is enough to overshoot dietary phenylalanine limits. Absolute contraindication.

ALDH2 / acetaldehyde metabolism: No direct relevance; mentioned only because spirulina's GLA content can mildly modulate inflammation in alcohol-related liver injury — preclinical only.

Beta-carotene + BCO1 polymorphism: BCO1 (β-carotene 15,15'-oxygenase) variants reduce vitamin A activation from carotenoid precursors. Spirulina is a substantial beta-carotene source; in BCO1-low-converter individuals (~30-50% of population), supplemental preformed retinol (cod liver oil) may be more efficient. Not a spirulina-specific issue but relevant for plant-based diets relying on spirulina for vitamin A.

MTHFR / folate metabolism: Spirulina's folate is naturally present but levels vary; not a major source. MTHFR C677T heterozygosity (~40% of population) is irrelevant to spirulina use specifically.

Dylan: Once 23andMe results land (June 2026), interpret HFE status. If C282Y carrier, deprioritize spirulina as iron-source rationale weakens. PKU is excluded by absence of newborn-screen flag in his history.

The single most important sourcing decision for spirulina is third-party heavy-metal + microcystin testing. Without this, the product is unsafe for chronic daily use regardless of brand reputation.

Decision rules:

1. Hawaiian Pacifica (Cyanotech) or Earthrise as default. Both routinely publish heavy-metal + microcystin COAs.
2. Tablets or capsules over powder unless taste is a non-issue. Easier compliance.
3. Request current-batch COA before purchase if buying any non-premium brand, especially in bulk. Look for explicit microcystin test results (LR variant is the most common contaminant).
4. Avoid "spirulina-chlorella blends" from non-Western suppliers — chlorella has its own contamination issues + the bundling makes COA interpretation harder.
5. EU and Japanese third-party-tested brands are also clean (e.g., Klamath, Algomed in Germany, Japanese suppliers under JFRL audit). Niche in US market.

For Dylan (if trialed): Hawaiian Pacifica tablets, 500 mg × 6/day, ~$30 for ~2 month supply. Lowest contamination risk in mass market, no taste issue, easy compliance.

Baseline (before starting)

• Ferritin + transferrin saturation — both for deficiency rationale and overload safety. CBC for hemoglobin/MCV.
• Lipid panel — TC, LDL, HDL, TG, ApoB if available.
• Resting BP — 3-day morning average from arm cuff.
• ALT, AST, GGT — liver-enzyme baseline (microcystin watch, though clean-source product makes this low-risk).
• hsCRP — inflammation baseline; expect modest reduction over 8-12 weeks if effect real.
• Fasting glucose + HbA1c — glycemic baseline; spirulina has mild glucose-lowering effect.
• HFE status — from 23andMe / pharmacogenomic panel if available.
• Subjective symptom diary — if used for allergic rhinitis, baseline severity score (e.g., TNSS — total nasal symptom score).

During use (3-6 month review)

• Lipid panel + BP recheck at 8-12 weeks — primary efficacy endpoints if used for cardiometabolic indication.
• Ferritin recheck at 12 weeks — confirm modest rise if used for iron support; watch for over-loading if stacked with multivitamin iron.
• ALT/AST at 6 months if chronic high-dose use — microcystin chronic-exposure check (low likelihood with Hawaiian Pacifica but cheap to verify).
• Subjective recovery / DOMS journaling for athletes — semi-objective signal.

Post-cycle (if discontinued)

• BP and lipids fade back over 4-8 weeks.
• Ferritin remains elevated if increased.